Key clinical point: Dupilumab treatment resulted in clinically relevant and statistically significant improvements in AD signs and symptoms in adolescents with moderate to severe atopic dermatitis.
Major finding: At week 16, a significantly higher proportion of patients in the dupilumab treatment groups had Investigator’s Global Assessment scores of 0/1, compared with those in the placebo group (24.4%, 17.9%, and 2.4%).
Study details: A phase 3 randomized trial of 251 adolescents with AD.
Disclosures: The study’s principal investigator was Amy S. Paller, MD. The study was funded by Sanofi Genzyme and Regeneron. Dr. Prescilla is an employee of Sanofi Genzyme.
REPORTING FROM SPD 2019